Geneos announced positive preliminary results of our ongoing first-in-human trial GT-30. GT-30 is a phase I/II trial of personalized vaccine, GNOS-PV02, in combination with plasmid pIL-12 and pembrolizumab in patients in second line advanced hepatocellular carcinoma (HCC).
VGXI and Geneos Therapeutics Expand Partnership for Personalized Cancer Immunotherapies
Geneos Therapeutics Secures $12 Million in Series A1 Financing to Advance Personalized Cancer Immunotherapy Programs
Geneos expands its lead program for treating patients with advanced hepatocellular carcinoma
Geneos adds to its leadership team
Geneos will be attending the following upcoming conferences:
VGXI Enables Rapid GMP DNA Manufacturing Timeline for Geneos Therapeutics Personalized Cancer Immunotherapy
Geneos Personalized Neoantigen-Targeting Vaccine (GNOS-PV02) to be Utilized in Innovative GT-30 Hepatocellular Carcinoma Trial
Geneos Therapeutics Named One of 11 Finalists for the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award. Niranjan Y. Sardesai, CEO of Geneos, presented at the Lyfebulb Helsinn Cancer Innovation Summit on January 30th, 2020 in Monaco.
Texas Based CMO VGXI and Geneos Therapeutics Establish Supply Agreement for Production of GT- EPIC-Based Personalized Cancer Therapeutics
